Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeDry
2023-510187-13-00Phase 3Authorised
- Sponsor
- Central Denmark Region
- Start
- Apr 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in overactive bladder (OAB) and urinary incontinence (UI) comparing Solifenacin monotherapy, Mirabegron monotherapy and Solifenacin + Mirabegron combination (3 arms). Primary endpoint: Treatment response (change in number of wet days per 7 days). Planned start Apr 2024; status: authorised.
02
Drugs
mirabegronsolifenacin
03
Conditions
overactive bladder (OAB)urinary incontinence (UI)
Beyond the preview
Go deeper on 2023-510187-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510187-13-00.